Placebo + MORF-057
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Diseases
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Trial Timeline
Jul 18, 2024 → Jun 1, 2030
NCT ID
NCT06226883About Placebo + MORF-057
Placebo + MORF-057 is a phase 2 stage product being developed by Eli Lilly for Inflammatory Bowel Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06226883. Target conditions include Inflammatory Bowel Diseases, Crohn's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06226883 | Phase 2 | Recruiting |
Competing Products
20 competing products in Inflammatory Bowel Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| CT-P13 | Celltrion | Phase 3 | 77 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 23 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| fidaxomicin | Astellas Pharma | Approved | 85 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 52 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Risankizumab | AbbVie | Approved | 85 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |